Cleared Traditional

GUGLIELMI DETACHABLE COIL (GDC) (K031049) - FDA 510(k) Clearance

Class II Neurology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K031049 · Boston Scientific, Target · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2003
Decision
121d
Days
Class 2
Risk

K031049 is an FDA 510(k) clearance for the GUGLIELMI DETACHABLE COIL (GDC). Classified as Device, Neurovascular Embolization (product code HCG), Class II - Special Controls.

Submitted by Boston Scientific, Target (Fremont, US). The FDA issued a Cleared decision on August 1, 2003 after a review of 121 days - within the typical 510(k) review window.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5950 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.

View all Boston Scientific, Target devices

Submission Details

510(k) Number K031049 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 02, 2003
Decision Date August 01, 2003
Days to Decision 121 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
27d faster than avg
Panel avg: 148d · This submission: 121d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code HCG Device, Neurovascular Embolization
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5950
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Peers - HCG Device, Neurovascular Embolization

All 43
Devices cleared under the same product code (HCG) and FDA review panel - the closest regulatory comparables to K031049.
GDC-10 360 DEGREE COIL SR
K042539 · Boston Scientific Corp · Oct 2004
CONTOUR SE MICROSPHERES (SYRINGE)
K032707 · Boston Scientific Corp · Sep 2003
MODIFICATION TO CONTOUR SE MICROSPHERES
K032542 · Boston Scientific Corp · Sep 2003
CONTOUR SE MICROSPHERES
K022427 · Boston Scientific Corp · Aug 2002
DETACH 18 AND DETACH 11, NEUROLOGICAL EMBOLIZATION COIL SYSTEM
K000651 · Cook, Inc. · Nov 2000
HILAL EMBOLIZATION MICROCOIL(TM)
K901337 · Cook, Inc. · Nov 1990